

PRESS RELEASE

**Appointment of Mr. Bernard Massiot
Chairman of the Executive Board of Guerbet Group**

Villepinte, 11 January 2010

The Supervisory Board of Guerbet that met on Monday, 11 January, under the chairmanship of Mr. Jean-Jacques Bertrand, appointed Mr. Bernard Massiot as chairman of the Executive Board of Guerbet, replacing Mr. Philippe Decazes. His appointment is destined to provide new momentum to the Group in achieving its objective of becoming a major player in the medical imaging sector.

The Supervisory Board unanimously thanked Mr. Philippe Decazes for the work he has accomplished over 15 years on behalf of the Guerbet Group, first within the Simafex subsidiary and then as a member of Group Management over the last 12 years. The Board paid homage to the results thus obtained in recent years.

Mr. Philippe Decazes will continue to support the Group's strategy as an advisor to the new Chairman.

Mr. Bernard Massiot, 54 years of age, is a graduate of Paris-Dauphine University and has a degree in Public Accounting. He began his career in audit and finance and subsequently general management in sectors including the press and media, industry (Northeast France) and services, primarily in France or in Europe.

Mr. Bernard Massiot has served as a Director of Guerbet Group since 1993 and as Vice Chairman of the Supervisory Board since 2006. He is also, moreover, a grandson of André Guerbet, the company's founder, and one of the nephews of Doctor Michel Guerbet.

Mr. Bernard Massiot has accordingly resigned from his functions on the Supervisory Board.

The Supervisory Board reaffirms its confidence in Guerbet's prospects for development and the ability of Group teams to successfully meet the challenges ahead.

Mr. Bernard Massiot stated: "*The goal of all shareholders and employees of Guerbet Group is to develop in the service of patients and healthcare systems. I am personally delighted to support this ambition.*"

About Guerbet

Guerbet is the only pharmaceutical group worldwide fully dedicated to medical imaging, with a comprehensive offering of x-ray, MRI contrast media and nuclear medicine products. Its products assist medical professionals (radiologists, cardiologists, oncologists, etc.) in better diagnosing and treating their patients (cardiovascular, cancer, inflammatory and degenerative diseases).

To develop new products and assure its future growth, every year Guerbet devotes significant resources to research and development with 180 R&D employees and an amount equivalent to approximately 10% of sales. MRI and nuclear medicine are key priorities of Guerbet's research programmes.

Guerbet is solidly positioned in Europe with a market share of 25% and is expanding its presence in the United States, Latin America and Asia.

Guerbet, listed on Eurolist Euronext Paris in compartment B had sales in 2008 of €321 million, with a total workforce of 1,270 employees.

For additional information about Guerbet, please consult: www.guerbet.com.

Media contact:

Amélie Pelletier, Thomas Doron

3d Communication, +33 (0) 1 46 05 87 87

apelletier@3dcommunication.fr, tdoron@3dcommunication.fr